Polydatin Inhibits NLRP3 Inflammasome in Dry Eye Disease by Attenuating Oxidative Stress and Inhibiting the NF-κB Pathway

Polydatin Inhibits NLRP3 Inflammasome in Dry Eye Disease by Attenuating Oxidative Stress and Inhibiting the NF-κB Pathway
复制标题

DOI:
10.3390/nu11112792
复制
发表时间:
2019-11-01
期刊:
影响因子:
5.9
通讯作者:
Kim, Chan-Sik
Kim, Chan-Sik
中科院分区:
医学2区
文献类型:
--
作者:
Park, Bongkyun;Jo, Kyuhyung;Kim, Chan-Sik

文献摘要

被引文献

相似文献

虎杖苷(Polydatin),也被称为pieceid, (E)-piceid, (E)-polydatin,反式Polydatin,或3,5,4'-三羟基二苯乙烯-3-b- d -葡萄糖苷)是从虎杖根和根茎中分离出来的单晶化合物。调查。(蓼科)。先前的一项研究表明,葡多糖具有抗氧化和抗炎作用。然而,多柚素在干眼病(DED)中的作用尚未阐明。采用眶外泪腺切除法建立DED大鼠模型。在体内,本研究表明,泪腺切除引起泪液减少、角膜严重不规则、损伤、泪膜破裂、杯状细胞丢失等变化,以及结膜组织炎症细胞因子和NLRP3表达增加。然而,这些变化可以通过滴眼液得到恢复。在体外,多果苷通过抑制nf - κ B向细胞核的易位以及tnf - α、IL-6、IL-1 β和MMP9的mRNA表达,抑制高渗应激诱导的炎症。此外,高渗应激诱导的NLRP3炎症小体通路和ROS的产生被多柚素抑制。我们的研究结果提供了深入了解多葡聚糖作为治疗DED的候选试剂的作用。
Polydatin (also named pieceid, (E)-piceid, (E)-polydatin, trans-polydatin, or 3,5,4'-trihydroxystilbene-3-b-D-glucoside) is a monocrystalline compound isolated from the root and rhizome of Polygonum cuspidatum Sieb. et Zucc. (Polygonaceae). A previous study showed that polydatin has antioxidant and anti-inflammatory effects. However, the effect of polydatin in dry eye disease (DED) has not been elucidated. DED rat models were induced by exorbital lacrimal gland-excision. In vivo, the present study showed that the excision of lacrimal glands induced changes such as reduced tear fluid, severe corneal irregularity, damage, tear film break, and goblet cell loss as well as increased inflammation cytokine and NLRP3 expression in conjunctival tissue. However, these changes were restored by polydatin eye dropping. In vitro, polydatin inhibited hyperosmolar stress-induced inflammation through attenuation of the translocation of NF-kappa B to the nucleus and the mRNA expression of TNF-alpha, IL-6, IL-1 beta, and MMP9. In addition, the hyperosmolar stress-induced NLRP3 inflammasome pathway and ROS production were inhibited by polydatin. Our findings provided insight into the effect of polydatin as a candidate reagent for the treatment of DED.